About this company
Humanized Multi-Organoid Disease Models operated by Dedicated Organoid Competence Centers abc biopply AG provides validated highly predictive preclinical CRO services for drug efficacy, safety, toxicity, resistance, and biomarker development based on its proprietary 3D CoSeedis humanized multi-organoid technology™ on clinically relevant disease models (e.g. oncology, neurology, hepatic, obesity etc.) In addition, the technology allows us to custom tailor or design any disease model and than license it to our clients for in-house implementation and scale up. Highlights of our Integrated Organoid Services: - Preclinical assays: drug efficacy, safety, toxicology, IC50, dose response, relapse and resistance studies - Disease models: oncology, neurology, hepatic, renal, and cartilage - Custom-tailored model development and biomarker discovery - Integrated preclinical services, from in vitro to in vivo, synchronized with humanized mouse models via our partner Preclina Together, these offerings enable faster, more reliable drug discovery while reducing reliance on animal testing.